263 related articles for article (PubMed ID: 26481538)
1. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.
Basińska-Ziobroń A; Daniel WA; Wójcikowski J
Pharmacol Rep; 2015 Dec; 67(6):1178-82. PubMed ID: 26481538
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
3. The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application.
Wójcikowski J; Basińska A; Daniel WA
Biochem Pharmacol; 2014 Jul; 90(2):188-95. PubMed ID: 24841887
[TBL] [Abstract][Full Text] [Related]
4. The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
Danek PJ; Wójcikowski J; Daniel WA
Pharmacol Rep; 2020 Dec; 72(6):1685-1694. PubMed ID: 32279279
[TBL] [Abstract][Full Text] [Related]
5. Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4.
Danek PJ; Basińska-Ziobroń A; Wójcikowski J; Daniel WA
Pharmacol Rep; 2021 Feb; 73(1):303-308. PubMed ID: 32888176
[TBL] [Abstract][Full Text] [Related]
6. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
Danek PJ; Wójcikowski J; Daniel WA
Toxicol Appl Pharmacol; 2020 Nov; 406():115239. PubMed ID: 32941854
[TBL] [Abstract][Full Text] [Related]
7. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Eur Neuropsychopharmacol; 2004 May; 14(3):199-208. PubMed ID: 15056479
[TBL] [Abstract][Full Text] [Related]
8. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver.
Daniel WA; Syrek M; Ryłko Z; Kot M
Pol J Pharmacol; 2001; 53(6):615-21. PubMed ID: 11985335
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
[TBL] [Abstract][Full Text] [Related]
10. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines.
Wójcikowski J; Boksa J; Daniel WA
Biochem Pharmacol; 2010 Oct; 80(8):1252-9. PubMed ID: 20615392
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
12. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study.
Wójcikowski J; Daniel WA
Pharmacol Rep; 2009; 61(5):851-8. PubMed ID: 19904008
[TBL] [Abstract][Full Text] [Related]
13. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
16. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
Prakash C; Kamel A; Cui D; Whalen RD; Miceli JJ; Tweedie D
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):35S-42S. PubMed ID: 10771452
[TBL] [Abstract][Full Text] [Related]
17. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
18. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
20. Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes.
McBride GM; Soo JY; Varcoe T; Morrison JL; Wiese MD
J Pharmacol Toxicol Methods; 2020; 106():106934. PubMed ID: 33080390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]